CY2619B2 - - Google Patents

Info

Publication number
CY2619B2
CY2619B2 CY201200011A CY1200011A CY2619B2 CY 2619 B2 CY2619 B2 CY 2619B2 CY 201200011 A CY201200011 A CY 201200011A CY 1200011 A CY1200011 A CY 1200011A CY 2619 B2 CY2619 B2 CY 2619B2
Authority
CY
Cyprus
Application number
CY201200011A
Other languages
Greek (el)
Inventor
Lars Thim
Birgitte Wulff
Martin Judge
Ole Madsen
Jens Holst
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26063575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2619(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of CY2619B2 publication Critical patent/CY2619B2/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CY201200011A 1996-03-01 2012-10-12 CY2619B2 (enExample)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK23096 1996-03-01
DK23196 1996-03-01
EP08103786A EP1975177B1 (en) 1996-03-01 1997-02-27 An appetite-suppressing peptide, its compositions and use

Publications (1)

Publication Number Publication Date
CY2619B2 true CY2619B2 (enExample) 2013-03-13

Family

ID=26063575

Family Applications (2)

Application Number Title Priority Date Filing Date
CY201200011A CY2619B2 (enExample) 1996-03-01 2012-10-12
CY2013008C CY2013008I2 (el) 1996-03-01 2013-02-27 Πεπτιδιο κατασταλτικο της ορεξης, συνθεσεις και χρηση αυτου

Family Applications After (1)

Application Number Title Priority Date Filing Date
CY2013008C CY2013008I2 (el) 1996-03-01 2013-02-27 Πεπτιδιο κατασταλτικο της ορεξης, συνθεσεις και χρηση αυτου

Country Status (22)

Country Link
EP (4) EP1975177B1 (enExample)
JP (1) JP4064460B2 (enExample)
KR (1) KR100611130B1 (enExample)
CN (1) CN1112367C (enExample)
AT (3) ATE505485T1 (enExample)
AU (1) AU710818B2 (enExample)
BR (1) BR9707807A (enExample)
CA (1) CA2246733C (enExample)
CY (2) CY2619B2 (enExample)
CZ (1) CZ297338B6 (enExample)
DE (3) DE69738695D1 (enExample)
DK (2) DK1975177T3 (enExample)
ES (3) ES2306685T3 (enExample)
FR (1) FR13C0009I2 (enExample)
HU (1) HU229234B1 (enExample)
IL (1) IL125805A0 (enExample)
NO (2) NO323043B1 (enExample)
PL (1) PL187095B1 (enExample)
PT (1) PT1975177E (enExample)
RU (1) RU2197261C2 (enExample)
UA (1) UA70283C2 (enExample)
WO (1) WO1997031943A1 (enExample)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
US6852690B1 (en) 1995-08-22 2005-02-08 Amylin Pharmaceuticals, Inc. Method and composition for enhanced parenteral nutrition
EP1975177B1 (en) * 1996-03-01 2011-04-13 Novo Nordisk A/S An appetite-suppressing peptide, its compositions and use
EP2275438A1 (en) 1996-04-12 2011-01-19 1149336 Ontario Inc. Glucagon-like peptide-2 analogs
US7235627B2 (en) 1996-08-30 2007-06-26 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6458924B2 (en) 1996-08-30 2002-10-01 Novo Nordisk A/S Derivatives of GLP-1 analogs
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP0941114B1 (en) * 1996-11-12 2005-02-23 Novo Nordisk A/S Use of glp-1 peptides
US6051557A (en) * 1997-05-16 2000-04-18 1149336 Ontario Inc. Methods of enhancing functioning of the upper gastrointestinal tract
WO1999014239A1 (de) * 1997-09-12 1999-03-25 Wolf Georg Forssmann Zusammensetzung zur therapie von diabetes mellitus und fettsucht
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
AU2712899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S Glp-2 derivatives with helix-content exceeding 25 percent, forming partially structured micellar-like aggregates
JP2002508162A (ja) * 1998-02-27 2002-03-19 ノボ ノルディスク アクティーゼルスカブ Ｎ末端を短縮したｇｌｐ−１誘導体
AU2610899A (en) * 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
WO1999047161A1 (en) * 1998-03-19 1999-09-23 Bionebraska, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
PT1326630E (pt) * 2000-09-18 2008-09-02 Sanos Bioscience As Utilização de péptidos glp-2
US7371721B2 (en) 2000-09-18 2008-05-13 Sanos Bioscience A/S Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
US7186683B2 (en) 2000-09-18 2007-03-06 Sanos Bioscience A/S Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
WO2002043709A1 (fr) 2000-12-01 2002-06-06 Takeda Chemical Industries, Ltd. Procede de production d'une preparation contenant une substance bioactive
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003059934A2 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin fusion proteins
CA2841097A1 (en) 2001-12-21 2003-07-24 Human Genome Sciences, Inc. Albumin and g-csf fusion proteins
US7411039B2 (en) 2002-10-14 2008-08-12 Novo Nordisk A/S GLP-2 compounds, formulations, and uses thereof
DE602004031927D1 (de) 2003-02-04 2011-05-05 Novo Nordisk As Injektionsvorrichtung mit drehbarer dosiseinstellungsvorrichtung
WO2005056036A2 (en) 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation of food preference using glp-1 agonists
EP2033662B1 (en) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Transglutaminase mediated conjugation of peptides
CN102816241B (zh) 2004-02-09 2015-07-22 人类基因科学公司 清蛋白融合蛋白
US7456254B2 (en) 2004-04-15 2008-11-25 Alkermes, Inc. Polymer-based sustained release device
CN1968700A (zh) * 2004-04-15 2007-05-23 阿尔克姆斯有限公司 聚合物基的持续释放装置
RU2262945C1 (ru) * 2004-04-29 2005-10-27 Закрытое акционерное общество "Научно-производственное предприятие "Тринита" Способ снижения массы тела в эксперименте на животных
US8410047B2 (en) 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
DE602006020123D1 (de) † 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
RS51319B (sr) 2005-09-22 2010-12-31 Biocompatibles Uk Limited GLP-l (GLUKAGON-LIKE PEPTID-l) FUZIONI POLIPEPTIDI SA POVEĆANOM OTPORNOSTI NA PEPTIDAZE
EP1854455B1 (en) 2006-05-10 2009-10-07 Biocompatibles UK Limited Spherical microcapsules comprising GLP-1 peptides, their production and use
PL2359808T3 (pl) 2006-08-09 2013-10-31 Intarcia Therapeutics Inc Osmotyczne systemy dostawcze i zespoły tłokowe
AU2007319066B2 (en) 2006-11-08 2013-09-19 Zealand Pharma A/S Selective glucagon-like-peptide-2 (GLP-2) analogues
EP2157967B1 (en) 2007-04-23 2013-01-16 Intarcia Therapeutics, Inc Suspension formulations of insulinotropic peptides and uses thereof
US20100278843A1 (en) * 2007-08-16 2010-11-04 St. Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (mic-1) activity
EP2240155B1 (en) 2008-02-13 2012-06-06 Intarcia Therapeutics, Inc Devices, formulations, and methods for delivery of multiple beneficial agents
ES2360782B1 (es) * 2009-07-28 2012-03-12 Grifols, S.A. Medios para cultivo de células de mamíferos que comprenden sobrenadante de etapas del fraccionamiento de Cohn y uso de los mismos.
EP3323423B1 (en) 2009-09-28 2020-06-17 Intarcia Therapeutics, Inc Rapid establishment and/or termination of substantial steady-state drug delivery
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EA028929B1 (ru) 2012-05-03 2018-01-31 Зилэнд Фарма А/С Аналоги глюкагоноподобного пептида-2 (glp-2)
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR101576126B1 (ko) 2014-12-29 2015-12-11 부경대학교 산학협력단 αＡＬ１４ 펩타이드를 유효성분으로 함유하는 신규 비만 예방 및 치료용 약학적 조성물
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
ES2968262T3 (es) 2015-06-03 2024-05-08 I2O Therapeutics Inc Sistemas de colocación de implantes
US10188135B2 (en) * 2015-11-04 2019-01-29 Stokley-Van Camp, Inc. Method for inducing satiety
KR101887576B1 (ko) * 2016-04-15 2018-08-13 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
KR20240037175A (ko) 2016-05-16 2024-03-21 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
KR102502040B1 (ko) 2016-12-09 2023-02-24 질랜드 파마 에이/에스 아실화 glp-1/glp-2 이중 효능제
AU2018206539A1 (en) 2017-01-03 2019-07-18 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
IL271245B2 (en) 2017-06-16 2023-10-01 Zealand Pharma As Dosing regimen for administration of glucagon-like peptide analog (GLP-2) 2
WO2020223761A1 (en) * 2019-05-06 2020-11-12 The University Of Sydney Methods for the fractionation of proteins

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203570A (en) 1978-08-23 1980-05-20 The Western States Machine Company Power-operated loading gate for centrifugal machines incorporating an auxiliary drive device
US4546082A (en) 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
DE3382547D1 (de) 1983-01-12 1992-05-27 Chiron Corp Sekretorische expression in eukaryoten.
JPS60501140A (ja) 1983-04-22 1985-07-25 アムジエン 酵母による外因性ポリペプチドの分泌
NZ207926A (en) 1983-04-25 1988-04-29 Genentech Inc Use of yeast #a#-factor to assist in expression of proteins heterologus to yeast
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
DK58285D0 (da) 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4632925A (en) * 1985-10-07 1986-12-30 Hoffmann-La Roche Inc. N-substituted diphenylpiperidines and antiobesity use thereof
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
JP2523562B2 (ja) 1985-10-25 1996-08-14 ザイモジェネティックス インコーポレーテッド 外来タンパク質を分泌することを目的としたｂａｒ１の使用法
AU607690B2 (en) 1985-12-24 1991-03-14 Marion Laboratories, Inc. Use of synthetic sulfated saccharides to enhance wound healing
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
US5024947A (en) 1987-07-24 1991-06-18 Cetus Corporation Serum free media for the growth on insect cells and expression of products thereby
DE3856247T2 (de) 1987-07-24 1999-04-29 Chiron Corp., Emeryville, Calif. Züchtung von insektenzellen mit airlift-reaktoren
DK463887D0 (da) 1987-09-07 1987-09-07 Novo Industri As Gaerleader
SU1697823A1 (ru) * 1988-08-01 1991-12-15 Киевский государственный институт усовершенствования врачей Способ лечени алиментарно-конституционального ожирени
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
AU4647889A (en) 1988-11-18 1990-06-12 Cetus Corporation Insect signal peptide mediated secretion of recombinant proteins
GB8910962D0 (en) 1989-05-12 1989-06-28 Natural Environment Res Novel baculovirus expression vectors and use thereof in the expression of foreign proteins in insects or insect cells
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
US5077214A (en) 1989-07-07 1991-12-31 The Texas A&M University System Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells
US5023328A (en) 1989-08-04 1991-06-11 The Texas A&M University System Lepidopteran AKH signal sequence
US5155037A (en) 1989-08-04 1992-10-13 The Texas A&M University System Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
DK300090D0 (da) 1990-12-19 1990-12-19 Novo Nordisk As Fremgangsmaade til fremstilling af leadersekvenser
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5990077A (en) * 1995-04-14 1999-11-23 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP1975177B1 (en) * 1996-03-01 2011-04-13 Novo Nordisk A/S An appetite-suppressing peptide, its compositions and use

Also Published As

Publication number Publication date
CY2013008I1 (el) 2015-08-05
CY2013008I2 (el) 2015-08-05
NO323043B1 (no) 2006-12-27
CZ297338B6 (cs) 2006-11-15
DK0891378T3 (da) 2003-01-06
EP1975177B1 (en) 2011-04-13
ATE505485T1 (de) 2011-04-15
EP1231218A3 (en) 2002-10-30
NO2013006I2 (enExample) 2013-03-12
DK1975177T3 (da) 2011-07-25
IL125805A0 (en) 1999-04-11
JP2000505460A (ja) 2000-05-09
EP2295453A3 (en) 2011-03-30
NO2013006I1 (no) 2013-04-02
RU2197261C2 (ru) 2003-01-27
ES2306685T3 (es) 2008-11-16
CZ273698A3 (cs) 1998-12-16
CA2246733A1 (en) 1997-09-04
BR9707807A (pt) 1999-07-27
DE69717092T2 (de) 2003-07-24
DE69740176D1 (de) 2011-05-26
ATE227737T1 (de) 2002-11-15
CA2246733C (en) 2010-07-20
UA70283C2 (en) 2004-10-15
EP0891378A1 (en) 1999-01-20
PL328732A1 (en) 1999-02-15
DE69738695D1 (de) 2008-06-26
WO1997031943A1 (en) 1997-09-04
HUP9902670A3 (en) 2000-02-28
NO984005D0 (no) 1998-08-31
EP1975177A1 (en) 2008-10-01
KR19990087439A (ko) 1999-12-27
PT1975177E (pt) 2011-07-26
EP1231218A2 (en) 2002-08-14
FR13C0009I2 (fr) 2013-08-16
ATE395359T1 (de) 2008-05-15
EP2295453A2 (en) 2011-03-16
AU710818B2 (en) 1999-09-30
AU1871597A (en) 1997-09-16
ES2187756T3 (es) 2003-06-16
EP0891378B1 (en) 2002-11-13
HU229234B1 (en) 2013-09-30
JP4064460B2 (ja) 2008-03-19
EP1231218B1 (en) 2008-05-14
DE69717092D1 (de) 2002-12-19
CN1112367C (zh) 2003-06-25
NO984005L (no) 1998-08-31
PL187095B1 (pl) 2004-05-31
ES2364705T3 (es) 2011-09-12
KR100611130B1 (ko) 2006-11-30
FR13C0009I1 (enExample) 2013-03-22
CN1215405A (zh) 1999-04-28

Similar Documents

Publication Publication Date Title
AR026660A2 (enExample)
BRPI9713914B8 (enExample)
IN183755B (enExample)
IN182289B (enExample)
IN187258B (enExample)
ITCN960005V0 (enExample)
ITMI960561V0 (enExample)
BR7601346U (enExample)
BR7600721U (enExample)
IN189985B (enExample)
ITMI960486V0 (enExample)
BR9603859A (enExample)
CN3043413S (enExample)
CN3042486S (enExample)
CN3041228S (enExample)
CN3042589S (enExample)
CN3039696S (enExample)
CN3043073S (enExample)
CN3040744S (enExample)
CN3039695S (enExample)
CN3040621S (enExample)
CN3043418S (enExample)
CN3043416S (enExample)
CN3041374S (enExample)
CN3039217S (enExample)